Anja Konig – Startup Investor Profile

Anja Konig, as the Global Head of Novartis Venture Fund, focuses on developing novel therapeutics and platforms, with particular interest in patient solutions and life sciences opportunities. Her investment check size involves rounds for companies like Epsilogen and Splice Bio. Anja Konig’s previous investments span pharmaceuticals, biotech, and medical devices. With a background at McKinsey, she has facilitated successful exits for companies like Heptares Therapeutics and Covagen. Anja Konig collaborates through entrepreneurship, venture philanthropy, and impact finance, aiming to create innovative solutions for societal challenges and promote market-led sustainable development.

Location:

Country: Germany

Investment Regions: EA, EU

Investment Stages: pre-seed, seed

Website: https://www.nvfund.com/#OurTeam

AI Reasoning: Search found Novartis Venture Fund participation in SpliceBio (NVF portfolio page) and press coverage of SpliceBio Series B on Jun 11, 2025 which lists participation by multiple venture investors; Novartis Venture Fund is listed on its portfolio page for SpliceBio. The investment date (Jun 11, 2025) is less than 5 months before the evaluation date, which places the last known investment in the 6 to 3 months range – corresponding to the classification returned. The startup involved: SpliceBio. Additionally, Epsilogen had activity on Sep 9, 2024, which is older than the SpliceBio date, so the most recent known investment is SpliceBio on Jun 11, 2025.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.